Semaglutide, compared with placebo, similarly improved HF-related symptoms, physical limitations, exercise function, and reduced inflammation and natriuretic peptides regardless of sex
You can start the weight loss program today, rather than waiting indefinitely for a new product to appear
If tirzepatide's dual-agonist approach interests you, check does tirzepatide burn fat for a mechanistic comparison
Understanding the incidence of fainting with semaglutide and identifying those at greatest risk is crucial for prevention and safety
Women ages 18 to 39 are the fastest-growing segment of people using GLP-1 drugs, growing from 7% to 14% among all U.S
FM: Resources, Data curation, Writing original draft